Amylyx Pharmaceuticals (AMLX) EBIT Margin (2021 - 2024)
Amylyx Pharmaceuticals (AMLX) posted EBIT Margin of 6392.14% for Q4 2024, up 135.15% on a QoQ basis from 18187.74% in Q3 2024, and up 639036.0% year-over-year from N/an in Q1 2024.
Powered by 
Analysis
Amylyx Pharmaceuticals (AMLX) EBIT Margin (2021 - 2024) Analysis & Trends
Amylyx Pharmaceuticals has reported EBIT Margin for 4 years, with the latest figure at 6392.14% in Q4 2024.
- On a quarterly basis, EBIT Margin rose 639036.0% year-over-year to 6392.14% in Q4 2024; TTM through Sep 2025 was 24739.15%, a 2487623.0% increase from a year earlier, with the FY2024 full-year figure at 360.1%, down 37029.0% from the prior year.
- EBIT Margin was 6392.14% for Q4 2024 at Amylyx Pharmaceuticals, up from 18187.74% in the prior quarter.
- The five-year high for EBIT Margin was 6392.14% in Q4 2024, with the low at 18187.74% in Q3 2024.
- Average EBIT Margin over 4 years is 3949.77%, with a median of 137.78% recorded in 2024.
- The sharpest annual moves came in 2023 and 2024: EBIT Margin soared 1586779 bps in 2023, then tumbled 1820597 bps in 2024.
- Over 4 years, EBIT Margin stood at 8041.4% in 2021, then surged by 97 bps to 203.76% in 2022, then jumped by 101 bps to 1.78% in 2023, then jumped by 358339 bps to 6392.14% in 2024.
- The last three EBIT Margin figures came in at 6392.14% (Q4 2024), 18187.74% (Q3 2024), and 7457.09% (Q2 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.88 Bn | 197.89 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 181.55 Bn | 178.37 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 132.31 Bn | 124.45 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 82.51 Bn | 74.52 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 61.54 Bn | 56.36 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 54.69 Bn | 49.55 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 34.07 Bn | 30.76 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.41 Bn | 30.12 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 30.10 Bn | 30.10 Bn | 1.16 Mn | -25,380.93% |
| 10 | Amylyx Pharmaceuticals | 3.69 Bn | 3.69 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 6,392.14% |
| Sep 30, 2024 | -18,187.74% |
| Jun 30, 2024 | -7,457.09% |
| Mar 31, 2024 | -137.78% |
| Dec 31, 2023 | 1.78% |
| Sep 30, 2023 | 18.23% |
| Jun 30, 2023 | 20.57% |
| Mar 31, 2023 | -2.87% |
| Dec 31, 2022 | -203.76% |
| Sep 30, 2022 | -15,849.57% |
| Sep 30, 2021 | -8,041.40% |